<DOC>
	<DOCNO>NCT01926899</DOCNO>
	<brief_summary>The objective study determine maximum tolerate dose ( MTD ) bortezomib combination calcineurin inhibitor methotrexate acute graft versus host disease ( aGVHD ) prophylaxis pediatric patient undergo allogeniec hematopoietic stem cell transplant ( alloHSCT )</brief_summary>
	<brief_title>A Multicenter Phase I Study Evaluating Addition Bortezomib Established Acute Graft Versus Host Disease Prophylaxis Regimen Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject childbearing potential agree practice 2 effective method contraception time sign informed consent form 30 day last dose bortezomib , agree completely abstain heterosexual intercourse . Male subject , even surgically sterilize ( i.e. , status postvasectomy ) must agree 1 following : practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse . Subjects must great equal 1 year old less 22 year old . Subjects must malignant nonmalignant condition require treatment alloHSCT Karnofsky Lansky performance score great 60 % Subjects must 9 10 ( HLA A , B , C , DR , DQ ) 10 10 HLA matchedrelated MUD bone marrow peripheral blood alloHSCT Subjects must meet institutional criterion alloHSCT â€¢ Patient great 1.5 time upper limit normal ( ULN ) Total Bilirubin Patient great equal Grade 2 peripheral neuropathy Patient myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . Patient hypersensitivity bortezomib , boron , mannitol . Female subject pregnant lactating . Confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( beta hCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Female patient lactate positive serum pregnancy test screening period , positive urine pregnancy test Day 1 first dose study drug , applicable . Serious medical psychiatric illness likely interfere participation clinical study . Diagnosed treat another malignancy within 2 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Participation clinical trial investigational agent include trial , within 14 day start trial throughout duration trial . Radiation therapy within 3 week randomization . Enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy . Current active infection per physician determination HIV positive Previous myeloablative autoHSCT alloHSCT previous 12 month ALT AST great 5 time ULN age Creatinine clearance glomerular filtration rate ( GFR ) less 60 ml/min/1.73 Shortening fraction le 26 % ejection fraction le 45 % Diffusing capacity carbon monoxide ( DLCO ) , volume exhale end first second force expiration ( FEV1 ) , diffusion capacity le 50 % predict ( correct hemoglobin ) ; unable perform lung function test , oxygen saturation le 94 % room air</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>